Key Highlights

  • ACADIA Pharmaceuticals shares are trading up 5.51% today to $28.65, building on Tuesday's 6.01% gain.
  • Second-quarter total revenue reached $308 million, beating consensus estimates of roughly $295.5 million by about 4%.
  • DAYBUE net sales grew 30% year-over-year to $125 million, driven by strong uptake of DAYBUE STIX.
  • NUPLAZID net sales rose 9% to 10% year-over-year, reaching $183 million on an adjusted basis.
  • Management raised full-year 2026 total revenue guidance to $1.24 billion to $1.30 billion, up from a prior range of $1.22 billion to $1.28 billion.

What's Driving Shares Today

ACADIA Pharmaceuticals (NASDAQ:ACAD) is a San Diego-based biopharmaceutical company focused on the development and commercialization of innovative medicines targeting central nervous system disorders and rare diseases in the United States. The company markets two FDA-approved products, NUPLAZID, the first and only approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, a novel synthetic analog approved for the treatment of Rett syndrome.

Shares are trading higher today after the company delivered a strong second-quarter beat, posting total revenue of $308 million versus consensus estimates near $295.5 million, driven by 30% growth in DAYBUE and 9% to 10% growth in NUPLAZID sales. Management also raised full-year 2026 revenue guidance to $1.24 billion to $1.30 billion from a prior range of $1.22 billion to $1.28 billion.

DAYBUE STIX Driving Growth

CEO Catherine Owen Adams said the results reflect strong commercial execution across both DAYBUE and NUPLAZID. DAYBUE STIX, a new formulation, has been adopted by approximately 40% of U.S. patients by quarter-end and is helping bring previously discontinued patients back to treatment. Management raised its 2026 DAYBUE guidance to $480 million to $510 million, while maintaining its long-term target of approximately $700 million in 2028 DAYBUE sales, with Europe expected to represent less than half of that figure.

DAYBUE also received a positive CHMP opinion from the European Medicines Agency recommending marketing authorization for Rett syndrome in adults and pediatric patients aged five and older, with a European Commission decision expected by the end of the third quarter and a planned German launch in early fourth quarter. If approved, DAYBUE would become the first authorized treatment for Rett syndrome in the European Union.

Pipeline Catalyst Ahead

Investors are also looking ahead to Phase 2 topline data for remlifanserin in Alzheimer's disease psychosis, expected between September and October 2026, a potential pipeline catalyst following the drug's July FDA Fast Track designation. NUPLAZID new patient prescriptions rose 20% year-over-year, with management maintaining its goal of approximately $1 billion in 2028 NUPLAZID sales as an expanded field force begins to contribute to growth.

Conclusion

ACADIA's revenue beat, combined with accelerating DAYBUE growth and a raised full-year outlook, suggests the company's two-product commercial engine continues to gain momentum even as investors look ahead to the remlifanserin data readout later this year. With no new company-specific catalysts today beyond the continued digestion of Tuesday's results, shares are extending gains as the market weighs the durability of this growth trajectory heading into the back half of 2026.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.